Top

Published in:

Open Access 01-04-2016 | Review

Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer

Authors: Maria Cristina Rangel, Daniel Bertolette, Nadia P. Castro, Malgorzata Klauzinska, Frank Cuttitta, David S. Salomon

Published in: Breast Cancer Research and Treatment | Issue 2/2016

Abstract

Cancer has been considered as temporal and spatial aberrations of normal development in tissues. Similarities between mammary embryonic development and cell transformation suggest that the underlying processes required for mammary gland development are also those perturbed during various stages of mammary tumorigenesis and breast cancer (BC) development. The master regulators of embryonic development Cripto-1, Notch/CSL, and Wnt/β-catenin play key roles in modulating mammary gland morphogenesis and cell fate specification in the embryo through fetal mammary stem cells (fMaSC) and in the adult organism particularly within the adult mammary stem cells (aMaSC), which determine mammary progenitor cell lineages that generate the basal/myoepithelial and luminal compartments of the adult mammary gland. Together with recognized transcription factors and embryonic stem cell markers, these embryonic regulatory molecules can be inappropriately augmented during tumorigenesis to support the tumor-initiating cell (TIC)/cancer stem cell (CSC) compartment, and the effects of their deregulation may contribute for the etiology of BC, in particular the most aggressive subtype of BC, triple-negative breast cancer (TNBC). This in depth review will present evidence of the involvement of Cripto-1, Notch/CSL, and Wnt/β-catenin in the normal mammary gland morphogenesis and tumorigenesis, from fMaSC/aMaSC regulation to TIC generation and maintenance in TNBC. Specific therapies for treating TNBC by targeting these embryonic pathways in TICs will be further discussed, providing new opportunities to destroy not only the bulk tumor, but also TICs that initiate and promote the metastatic spread and recurrence of this aggressive subtype of BC.

Fu N, Lindeman GJ, Visvader JE (2014) The mammary stem cell hierarchy. Curr Top Dev Biol 107:133–160. doi:10.1016/B978-0-12-416022-4.00005-6 PubMedCrossRef

Sternlicht MD, Kouros-Mehr H, Lu P, Werb Z (2006) Hormonal and local control of mammary branching morphogenesis. Differentiation 74(7):365–381. doi:10.1111/j.1432-0436.2006.00105.x PubMedPubMedCentralCrossRef

Robinson GW (2007) Cooperation of signalling pathways in embryonic mammary gland development. Nat Rev Genet 8(12):963–972. doi:10.1038/nrg2227 PubMedCrossRef

Rangel MC, Karasawa H, Castro NP, Nagaoka T, Salomon DS, Bianco C (2012) Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. Am J Pathol 180(6):2188–2200. doi:10.1016/j.ajpath.2012.02.031 PubMedPubMedCentralCrossRef

Howard B, Ashworth A (2006) Signalling pathways implicated in early mammary gland morphogenesis and breast cancer. PLoS Genet 2(8):e112. doi:10.1371/journal.pgen.0020112 PubMedPubMedCentralCrossRef

Ravisankar V, Singh TP, Manoj N (2011) Molecular evolution of the EGF-CFC protein family. Gene 482(1–2):43–50. doi:10.1016/j.gene.2011.05.007 PubMedCrossRef

Klauzinska M, Castro NP, Rangel MC, Spike BT, Gray PC, Bertolette D, Cuttitta F, Salomon D (2014) The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition. Semin Cancer Biol 29:51–58. doi:10.1016/j.semcancer.2014.08.003 PubMedCrossRef

Minchiotti G, Parisi S, Liguori G, Signore M, Lania G, Adamson ED, Lago CT, Persico MG (2000) Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development. Mech Dev 90(2):133–142PubMedCrossRef

Gray PC, Vale W (2012) Cripto/GRP78 modulation of the TGF-beta pathway in development and oncogenesis. FEBS Lett 586(14):1836–1845. doi:10.1016/j.febslet.2012.01.051 PubMedPubMedCentralCrossRef

10.

Nagaoka T, Karasawa H, Turbyville T, Rangel MC, Castro NP, Gonzales M, Baker A, Seno M, Lockett S, Greer YE, Rubin JS, Salomon DS, Bianco C (2013) Cripto-1 enhances the canonical Wnt/beta-catenin signaling pathway by binding to LRP5 and LRP6 co-receptors. Cell Signal 25(1):178–189. doi:10.1016/j.cellsig.2012.09.024 PubMedPubMedCentralCrossRef

11.

Bianco C, Wechselberger C, Ebert A, Khan NI, Sun Y, Salomon DS (2001) Identification of Cripto-1 in human milk. Breast Cancer Res Treat 66(1):1–7PubMedCrossRef

12.

Klauzinska M, McCurdy D, Rangel MC, Vaidyanath A, Castro NP, Shen MM, Gonzales M, Bertolette D, Bianco C, Callahan R, Salomon DS, Raafat A (2015) Cripto-1 ablation disrupts alveolar development in the mouse mammary gland through a progesterone receptor-mediated pathway. Am J Pathol 185(11):2907–2922. doi:10.1016/j.ajpath.2015.07.023 PubMedCrossRef

13.

Izrailit J, Reedijk M (2012) Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications. Cancer Lett 317(2):115–126. doi:10.1016/j.canlet.2011.11.028 PubMedCrossRef

14.

Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB (2010) Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 70(2):709–718. doi:10.1158/0008-5472.CAN-09-1681 PubMedPubMedCentralCrossRef

15.

Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8(2):97–106. doi:10.1038/nrclinonc.2010.196 PubMedCrossRef

16.

Raafat A, Goldhar AS, Klauzinska M, Xu K, Amirjazil I, McCurdy D, Lashin K, Salomon D, Vonderhaar BK, Egan S, Callahan R (2011) Expression of Notch receptors, ligands, and target genes during development of the mouse mammary gland. J Cell Physiol 226(7):1940–1952. doi:10.1002/jcp.22526 PubMedPubMedCentralCrossRef

17.

Jhappan C, Gallahan D, Stahle C, Chu E, Smith GH, Merlino G, Callahan R (1992) Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev 6(3):345–355PubMedCrossRef

18.

Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E, Callahan R, Merlino G, Smith GH (1996) Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res 56(8):1775–1785PubMed

19.

Morkel M, Huelsken J, Wakamiya M, Ding J, van de Wetering M, Clevers H, Taketo MM, Behringer RR, Shen MM, Birchmeier W (2003) Beta-catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development 130(25):6283–6294. doi:10.1242/dev.00859 PubMedCrossRef

20.

Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434(7035):843–850. doi:10.1038/nature03319 PubMedCrossRef

21.

Boras-Granic K, Hamel PA (2013) Wnt-signalling in the embryonic mammary gland. J Mammary Gland Biol Neoplasia 18(2):155–163. doi:10.1007/s10911-013-9280-x PubMedCrossRef

22.

Incassati A, Chandramouli A, Eelkema R, Cowin P (2010) Key signaling nodes in mammary gland development and cancer: beta-catenin. Breast Cancer Res 12(6):213. doi:10.1186/bcr2723 PubMedPubMedCentralCrossRef

23.

Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107(7):2989–2994. doi:10.1073/pnas.0915148107 PubMedPubMedCentralCrossRef

24.

Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, McMahon JA, McMahon AP, Weinberg RA (2000) Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 14(6):650–654PubMedPubMedCentral

25.

Alexander CM, Goel S, Fakhraldeen SA, Kim S (2012) Wnt signaling in mammary glands: plastic cell fates and combinatorial signaling. Cold Spring Harb Perspect Biol. doi:10.1101/cshperspect.a008037 PubMedPubMedCentral

26.

Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands T, Egeblad M, Cowin P, Werb Z, Tan LK, Rosen JM, Varmus HE (2003) Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 100(26):15853–15858. doi:10.1073/pnas.2136825100 PubMedPubMedCentralCrossRef

27.

Spike BT, Engle DD, Lin JC, Cheung SK, La J, Wahl GM (2012) A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell 10(2):183–197. doi:10.1016/j.stem.2011.12.018 PubMedPubMedCentralCrossRef

28.

Makarem M, Kannan N, Nguyen LV, Knapp DJ, Balani S, Prater MD, Stingl J, Raouf A, Nemirovsky O, Eirew P, Eaves CJ (2013) Developmental changes in the in vitro activated regenerative activity of primitive mammary epithelial cells. PLoS Biol 11(8):e1001630. doi:10.1371/journal.pbio.1001630 PubMedPubMedCentralCrossRef

29.

Kenney NJ, Smith GH, Lawrence E, Barrett JC, Salomon DS (2001) Identification of stem cell units in the terminal end bud and duct of the mouse mammary gland. J Biomed Biotechnol 1(3):133–143. doi:10.1155/S1110724301000304 PubMedPubMedCentralCrossRef

30.

Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J, Sharma N, Dekoninck S, Blanpain C (2011) Distinct stem cells contribute to mammary gland development and maintenance. Nature 479(7372):189–193. doi:10.1038/nature10573 PubMedCrossRef

31.

Rios AC, Fu NY, Lindeman GJ, Visvader JE (2014) In situ identification of bipotent stem cells in the mammary gland. Nature 506(7488):322–327. doi:10.1038/nature12948 PubMedCrossRef

32.

Deugnier MA, Teuliere J, Faraldo MM, Thiery JP, Glukhova MA (2002) The importance of being a myoepithelial cell. Breast Cancer Res 4(6):224–230PubMedPubMedCentralCrossRef

33.

Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J, Lindeman GJ, Visvader JE (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9(2):201–209. doi:10.1038/ncb1530 PubMedCrossRef

34.

Sakai D, Suzuki T, Osumi N, Wakamatsu Y (2006) Cooperative action of Sox9, Snail2 and PKA signaling in early neural crest development. Development 133(7):1323–1333. doi:10.1242/dev.02297 PubMedCrossRef

35.

Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zurrer-Hardi U, Bell G, Tam WL, Mani SA, van Oudenaarden A, Weinberg RA (2012) Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148(5):1015–1028. doi:10.1016/j.cell.2012.02.008 PubMedPubMedCentralCrossRef

36.

Nassour M, Idoux-Gillet Y, Selmi A, Come C, Faraldo ML, Deugnier MA, Savagner P (2012) Slug controls stem/progenitor cell growth dynamics during mammary gland morphogenesis. PLoS ONE 7(12):e53498. doi:10.1371/journal.pone.0053498 PubMedPubMedCentralCrossRef

37.

Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek KD, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard MA, Chodosh LA, Pfeffer PL, Lindeman GJ, Visvader JE, Ormandy CJ (2008) The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev 22(5):581–586. doi:10.1101/gad.1614608 PubMedPubMedCentralCrossRef

38.

Chakrabarti R, Wei Y, Romano RA, DeCoste C, Kang Y, Sinha S (2012) Elf5 regulates mammary gland stem/progenitor cell fate by influencing notch signaling. Stem Cells 30(7):1496–1508. doi:10.1002/stem.1112 PubMedCrossRef

39.

Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukacisin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, Kang Y (2012) Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol 14(11):1212–1222. doi:10.1038/ncb2607 PubMedPubMedCentralCrossRef

40.

Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. doi:10.1038/nature11412 CrossRef

41.

Hein SM, Haricharan S, Johnston AN, Toneff MJ, Reddy JP, Dong J, Bu W, Li Y (2015) Luminal epithelial cells within the mammary gland can produce basal cells upon oncogenic stress. Oncogene. doi:10.1038/onc.2015.206

42.

Buono KD, Robinson GW, Martin C, Shi S, Stanley P, Tanigaki K, Honjo T, Hennighausen L (2006) The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev Biol 293(2):565–580. doi:10.1016/j.ydbio.2006.02.043 PubMedCrossRef

43.

Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ (2010) BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7(3):403–417. doi:10.1016/j.stem.2010.07.010 PubMedCrossRef

44.

Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8):907–913. doi:10.1038/nm.2000 PubMedCrossRef

45.

Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, Wong KY, Sung KW, Lee CW, Zhao XD, Chiu KP, Lipovich L, Kuznetsov VA, Robson P, Stanton LW, Wei CL, Ruan Y, Lim B, Ng HH (2006) The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 38(4):431–440. doi:10.1038/ng1760 PubMedCrossRef

46.

Vallier L, Mendjan S, Brown S, Chng Z, Teo A, Smithers LE, Trotter MW, Cho CH, Martinez A, Rugg-Gunn P, Brons G, Pedersen RA (2009) Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. Development 136(8):1339–1349. doi:10.1242/dev.033951 PubMedPubMedCentralCrossRef

47.

Simoes BM, Piva M, Iriondo O, Comaills V, Lopez-Ruiz JA, Zabalza I, Mieza JA, Acinas O, Vivanco MD (2011) Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res Treat 129(1):23–35. doi:10.1007/s10549-010-1169-4 PubMedCrossRef

48.

Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE (2005) Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26(2):495–502. doi:10.1093/carcin/bgh321 PubMedCrossRef

49.

Spike BT, Kelber JA, Booker E, Kalathur M, Rodewald R, Lipianskaya J, La J, He M, Wright T, Klemke R, Wahl GM, Gray PC (2014) CRIPTO/GRP78 signaling maintains fetal and adult mammary stem cells ex vivo. Stem Cell Reports 2(4):427–439. doi:10.1016/j.stemcr.2014.02.010 PubMedPubMedCentralCrossRef

50.

Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS (2004) Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6(6):R605–R615. doi:10.1186/bcr920 PubMedPubMedCentralCrossRef

51.

Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M, Iscove N, Jones S, McKinney S, Emerman J, Aparicio S, Marra M, Eaves C (2008) Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 3(1):109–118. doi:10.1016/j.stem.2008.05.018 PubMedCrossRef

52.

Lafkas D, Rodilla V, Huyghe M, Mourao L, Kiaris H, Fre S (2013) Notch3 marks clonogenic mammary luminal progenitor cells in vivo. J Cell Biol 203(1):47–56. doi:10.1083/jcb.201307046 PubMedPubMedCentralCrossRef

53.

Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, Lindeman GJ, Visvader JE (2008) Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3(4):429–441. doi:10.1016/j.stem.2008.08.001 PubMedCrossRef

54.

Rodilla V, Dasti A, Huyghe M, Lafkas D, Laurent C, Reyal F, Fre S (2015) Luminal progenitors restrict their lineage potential during mammary gland development. PLoS Biol 13(2):e1002069. doi:10.1371/journal.pbio.1002069 PubMedPubMedCentralCrossRef

55.

Zeng YA, Nusse R (2010) Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 6(6):568–577. doi:10.1016/j.stem.2010.03.020 PubMedPubMedCentralCrossRef

56.

van Amerongen R, Bowman AN, Nusse R (2012) Developmental stage and time dictate the fate of Wnt/beta-catenin-responsive stem cells in the mammary gland. Cell Stem Cell 11(3):387–400. doi:10.1016/j.stem.2012.05.023 PubMedCrossRef

57.

Plaks V, Brenot A, Lawson DA, Linnemann JR, Van Kappel EC, Wong KC, de Sauvage F, Klein OD, Werb Z (2013) Lgr5-expressing cells are sufficient and necessary for postnatal mammary gland organogenesis. Cell Rep 3(1):70–78. doi:10.1016/j.celrep.2012.12.017 PubMedPubMedCentralCrossRef

58.

de Visser KE, Ciampricotti M, Michalak EM, Tan DW, Speksnijder EN, Hau CS, Clevers H, Barker N, Jonkers J (2012) Developmental stage-specific contribution of LGR5(+) cells to basal and luminal epithelial lineages in the postnatal mammary gland. J Pathol 228(3):300–309. doi:10.1002/path.4096 PubMedCrossRef

59.

Badders NM, Goel S, Clark RJ, Klos KS, Kim S, Bafico A, Lindvall C, Williams BO, Alexander CM (2009) The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. PLoS ONE 4(8):e6594. doi:10.1371/journal.pone.0006594 PubMedPubMedCentralCrossRef

60.

Gu B, Watanabe K, Sun P, Fallahi M, Dai X (2013) Chromatin effector Pygo2 mediates Wnt-notch crosstalk to suppress luminal/alveolar potential of mammary stem and basal cells. Cell Stem Cell 13(1):48–61. doi:10.1016/j.stem.2013.04.012 PubMedPubMedCentralCrossRef

61.

Meier-Abt F, Milani E, Roloff T, Brinkhaus H, Duss S, Meyer DS, Klebba I, Balwierz PJ, van Nimwegen E, Bentires-Alj M (2013) Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium. Breast Cancer Res 15(2):R36. doi:10.1186/bcr3419 PubMedPubMedCentralCrossRef

62.

Visvader JE (2011) Cells of origin in cancer. Nature 469(7330):314–322. doi:10.1038/nature09781 PubMedCrossRef

63.

Skibinski A, Kuperwasser C (2015) The origin of breast tumor heterogeneity. Oncogene 34(42):5309–5316. doi:10.1038/onc.2014.475 PubMedCrossRef

64.

Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5(1):5–23. doi:10.1016/j.molonc.2010.11.003 PubMedCrossRef

65.

Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76. doi:10.1186/gb-2007-8-5-r76 PubMedPubMedCentralCrossRef

66.

Ruggiero D, Nappo S, Nutile T, Sorice R, Talotta F, Giorgio E, Bellenguez C, Leutenegger AL, Liguori GL, Ciullo M (2015) Genetic variants modulating CRIPTO serum levels identified by genome-wide association study in Cilento isolates. PLoS Genet 11(1):e1004976. doi:10.1371/journal.pgen.1004976 PubMedPubMedCentralCrossRef

67.

Sato M, Yao VJ, Arap W, Pasqualini R (2010) GRP78 signaling hub a receptor for targeted tumor therapy. Adv Genet 69:97–114. doi:10.1016/S0065-2660(10)69006-2 PubMedCrossRef

68.

Tsai YL, Zhang Y, Tseng CC, Stanciauskas R, Pinaud F, Lee AS (2015) Characterization and mechanism of stress-induced translocation of 78-kilodalton glucose-regulated protein (GRP78) to the cell surface. J Biol Chem 290(13):8049–8064. doi:10.1074/jbc.M114.618736 PubMedCrossRefPubMedCentral

69.

Shani G, Fischer WH, Justice NJ, Kelber JA, Vale W, Gray PC (2008) GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth. Mol Cell Biol 28(2):666–677. doi:10.1128/MCB.01716-07 PubMedPubMedCentralCrossRef

70.

Pilli VS, Gupta K, Kotha BP, Aradhyam GK (2015) Snail-mediated Cripto-1 repression regulates the cell cycle and epithelial-mesenchymal transition-related gene expression. FEBS Lett 589(11):1249–1256. doi:10.1016/j.febslet.2015.04.005 PubMedCrossRef

71.

Strizzi L, Bianco C, Normanno N, Seno M, Wechselberger C, Wallace-Jones B, Khan NI, Hirota M, Sun Y, Sanicola M, Salomon DS (2004) Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol 201(2):266–276. doi:10.1002/jcp.20062 PubMedCrossRef

72.

Zhang DM, Bao YL, Yu CL, Wang YM, Song ZB (2015) Cripto-1 modulates macrophage cytokine secretion and phagocytic activity via NF-kappaB signaling. Immunol Res. doi:10.1007/s12026-015-8724-3

73.

Watanabe K, Nagaoka T, Lee JM, Bianco C, Gonzales M, Castro NP, Rangel MC, Sakamoto K, Sun Y, Callahan R, Salomon DS (2009) Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1. J Cell Biol 187(3):343–353. doi:10.1083/jcb.200905105 PubMedPubMedCentralCrossRef

74.

Dai X, Li Y, Bai Z, Tang XQ (2015) Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers. Sci Rep 5:14499. doi:10.1038/srep14499 PubMedPubMedCentralCrossRef

75.

Karamboulas C, Ailles L (2013) Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta 1830(2):2481–2495. doi:10.1016/j.bbagen.2012.11.008 PubMedCrossRef

76.

Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, Kluk M, Laskey J, Haines BB, Moskaluk C, Zawel L, Fawell S, Gilliland G, Zhang T, Kremer BE, Knoechel B, Bernstein BE, Pear WS, Liu XS, Aster JC, Sathyanarayanan S (2014) Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov 4(10):1154–1167. doi:10.1158/2159-8290.CD-13-0830 PubMedPubMedCentralCrossRef

77.

Shawber CJ, Funahashi Y, Francisco E, Vorontchikhina M, Kitamura Y, Stowell SA, Borisenko V, Feirt N, Podgrabinska S, Shiraishi K, Chawengsaksophak K, Rossant J, Accili D, Skobe M, Kitajewski J (2007) Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Investig 117(11):3369–3382. doi:10.1172/JCI24311 PubMedPubMedCentralCrossRef

78.

Abravanel DL, Belka GK, Pan TC, Pant DK, Collins MA, Sterner CJ, Chodosh LA (2015) Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Investig 125(6):2484–2496. doi:10.1172/JCI74883 PubMedPubMedCentralCrossRef

79.

Shao S, Zhao X, Zhang X, Luo M, Zuo X, Huang S, Wang Y, Gu S, Zhao X (2015) Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner. Mol Cancer 14:28. doi:10.1186/s12943-015-0295-3 PubMedPubMedCentralCrossRef

80.

Aristizabal-Pachon AF, Carvalho TI, Carrara HH, Andrade J, Takahashi CS (2015) AXIN2 polymorphisms, the beta-catenin destruction complex expression profile and breast cancer susceptibility. Asian Pac J Cancer Prev 16(16):7277–7284PubMedCrossRef

81.

Vadnais C, Shooshtarizadeh P, Rajadurai CV, Lesurf R, Hulea L, Davoudi S, Cadieux C, Hallett M, Park M, Nepveu A (2014) Autocrine Activation of the Wnt/beta-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers. Biol Open 3(10):937–946. doi:10.1242/bio.20148193 PubMedPubMedCentralCrossRef

82.

Elsarraj HS, Hong Y, Valdez KE, Michaels W, Hook M, Smith WP, Chien J, Herschkowitz JI, Troester MA, Beck M, Inciardi M, Gatewood J, May L, Cusick T, McGinness M, Ricci L, Fan F, Tawfik O, Marks JR, Knapp JR, Yeh HW, Thomas P, Carrasco DR, Fields TA, Godwin AK, Behbod F (2015) Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Breast Cancer Res 17:128. doi:10.1186/s13058-015-0630-z PubMedPubMedCentralCrossRef

83.

Pillai SG, Dasgupta N, Siddappa CM, Watson MA, Fleming T, Trinkaus K, Aft R (2015) Paired-like Homeodomain Transcription factor 2 expression by breast cancer bone marrow disseminated tumor cells is associated with early recurrent disease development. Breast Cancer Res Treat 153(3):507–517. doi:10.1007/s10549-015-3576-z PubMedPubMedCentralCrossRef

84.

Bianco C, Rangel MC, Castro NP, Nagaoka T, Rollman K, Gonzales M, Salomon DS (2010) Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol 177(2):532–540. doi:10.2353/ajpath.2010.100102 PubMedPubMedCentralCrossRef

85.

Soady KJ, Kendrick H, Gao Q, Tutt A, Zvelebil M, Ordonez LD, Quist J, Tan DW, Isacke CM, Grigoriadis A, Smalley MJ (2015) Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. Breast Cancer Res 17:31. doi:10.1186/s13058-015-0539-6 PubMedPubMedCentralCrossRef

86.

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12(5):R68. doi:10.1186/bcr2635 PubMedPubMedCentralCrossRef

87.

Visvader JE, Stingl J (2014) Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev 28(11):1143–1158. doi:10.1101/gad.242511.114 PubMedPubMedCentralCrossRef

88.

Pfefferle AD, Spike BT, Wahl GM, Perou CM (2015) Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy. Breast Cancer Res Treat 149(2):425–437. doi:10.1007/s10549-014-3262-6 PubMedPubMedCentralCrossRef

89.

Hadjimichael C, Chanoumidou K, Papadopoulou N, Arampatzi P, Papamatheakis J, Kretsovali A (2015) Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells 7(9):1150–1184. doi:10.4252/wjsc.v7.i9.1150 PubMedPubMedCentral

90.

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715. doi:10.1016/j.cell.2008.03.027 PubMedPubMedCentralCrossRef

91.

Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890. doi:10.1016/j.cell.2009.11.007 PubMedCrossRef

92.

Kim RJ, Nam JS (2011) OCT4 expression enhances features of cancer stem cells in a mouse model of breast cancer. Lab Anim Res 27(2):147–152. doi:10.5625/lar.2011.27.2.147 PubMedPubMedCentralCrossRef

93.

Lu X, Mazur SJ, Lin T, Appella E, Xu Y (2014) The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. Oncogene 33(20):2655–2664. doi:10.1038/onc.2013.209 PubMedPubMedCentralCrossRef

94.

Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J (2007) Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 20(4):474–481. doi:10.1038/modpathol.3800760 PubMedCrossRef

95.

Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40(5):499–507. doi:10.1038/ng.127 PubMedPubMedCentralCrossRef

96.

de Castro NP, Rangel MC, Nagaoka T, Salomon DS, Bianco C (2010) Cripto-1: an embryonic gene that promotes tumorigenesis. Future Oncol 6(7):1127–1142. doi:10.2217/fon.10.68 PubMedCrossRef

97.

Micalizzi DS, Ford HL (2009) Epithelial-mesenchymal transition in development and cancer. Future Oncol 5(8):1129–1143. doi:10.2217/fon.09.94 PubMedCrossRef

98.

Strizzi L, Abbott DE, Salomon DS, Hendrix MJ (2008) Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle 7(13):1931–1935PubMedPubMedCentralCrossRef

99.

Bianco C, Castro NP, Baraty C, Rollman K, Held N, Rangel MC, Karasawa H, Gonzales M, Strizzi L, Salomon DS (2013) Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells. J Cell Physiol 228(6):1174–1188. doi:10.1002/jcp.24271 PubMedPubMedCentralCrossRef

100.

Castro NP, Fedorova-Abrams ND, Merchant AS, Rangel MC, Nagaoka T, Karasawa H, Klauzinska M, Hewitt SM, Biswas K, Sharan SK, Salomon DS (2015) Cripto-1 as a novel therapeutic target for triple negative breast cancer. Oncotarget 6(14):11910–11929PubMedPubMedCentralCrossRef

101.

D’Angelo RC, Ouzounova M, Davis A, Choi D, Tchuenkam SM, Kim G, Luther T, Quraishi AA, Senbabaoglu Y, Conley SJ, Clouthier SG, Hassan KA, Wicha MS, Korkaya H (2015) Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity. Mol Cancer Ther 14(3):779–787. doi:10.1158/1535-7163.MCT-14-0228 PubMedPubMedCentralCrossRef

102.

Simmons MJ, Serra R, Hermance N, Kelliher MA (2012) NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro. Breast Cancer Res 14(5):R126. doi:10.1186/bcr3321 PubMedPubMedCentralCrossRef

103.

Simoes BM, O’Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro A, Alferez DG, Spence K, Santiago-Gomez A, Chemi F, Acar A, Gandhi A, Howell A, Brennan K, Ryden L, Catalano S, Ando S, Gee J, Ucar A, Sims AH, Marangoni E, Farnie G, Landberg G, Howell SJ, Clarke RB (2015) Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity. Cell Rep 12(12):1968–1977. doi:10.1016/j.celrep.2015.08.050 PubMedPubMedCentralCrossRef

104.

Jang GB, Kim JY, Cho SD, Park KS, Jung JY, Lee HY, Hong IS, Nam JS (2015) Blockade of Wnt/beta-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Sci Rep 5:12465. doi:10.1038/srep12465 PubMedCrossRef

105.

Tzeng HE, Yang L, Chen K, Wang Y, Liu YR, Pan SL, Gaur S, Hu S, Yen Y (2015) The pan-PI3 K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget 6(13):11061–11073PubMedPubMedCentralCrossRef

106.

Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, Mailo D, Palaia R, D’Aiuto G, Botti G, Perrone F, Salomon DS, Normanno N (2006) Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res 12(17):5158–5164. doi:10.1158/1078-0432.CCR-06-0274 PubMedCrossRef

107.

Gong YP, Yarrow PM, Carmalt HL, Kwun SY, Kennedy CW, Lin BP, Xing PX, Gillett DJ (2007) Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. Eur J Surg Oncol 33(4):438–443. doi:10.1016/j.ejso.2006.10.014 PubMedCrossRef

108.

Zhong XY, Zhang LH, Jia SQ, Shi T, Niu ZJ, Du H, Zhang GG, Hu Y, Lu AP, Li JY, Ji JF (2008) Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology 52(5):560–568. doi:10.1111/j.1365-2559.2008.02971.x PubMedCrossRef

109.

Klauzinska M, Bertolette D, Tippireddy S, Strizzi L, Gray PC, Gonzales M, Duroux M, Ruvo M, Wechselberger C, Castro NP, Rangel MC, Foca A, Sandomenico A, Hendrix MJ, Salomon D, Cuttitta F (2015) Cripto-1: an extracellular protein—connecting the sequestered biological dots. Connect Tissue Res 56(5):364–380. doi:10.3109/03008207.2015.1077239 PubMedCrossRef

110.

Biogen-Idec (2011) A phase I study of BIIB015 in relapsed/refractory solid tumors. vol NCT00674947

111.

Kelly RK, Olson DL, Sun Y, Wen D, Wortham KA, Antognetti G, Cheung AE, Orozco OE, Yang L, Bailly V, Sanicola M (2011) An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer 47(11):1736–1746. doi:10.1016/j.ejca.2011.02.023 PubMedCrossRef

112.

Ligtenberg MA, Witt K, Galvez-Cancino F, Sette A, Lladser A, Kiessling R (2016) Cripto-1 vaccination elicits protective immunity against metastatic melanoma. OncoImmunology. doi:10.1080/2162402X.2015.1128613

113.

Xu J, Song F, Jin T, Qin J, Wu J, Wang M, Wang Y, Liu J (2015) Prognostic values of Notch receptors in breast cancer. Tumour Biol. doi:10.1007/s13277-015-3961-6

114.

Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65(18):8530–8537. doi:10.1158/0008-5472.CAN-05-1069 PubMedCrossRef

115.

Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol 12(8):445–464. doi:10.1038/nrclinonc.2015.61 PubMedPubMedCentralCrossRef

116.

Hirose H, Ishii H, Mimori K, Ohta D, Ohkuma M, Tsujii H, Saito T, Sekimoto M, Doki Y, Mori M (2010) Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors. Oncol Rep 23(1):35–43PubMed

117.

Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL (2002) Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol 196(2):145–153. doi:10.1002/path.1035 PubMedCrossRef

118.

Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS (2011) beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24(2):209–231. doi:10.1038/modpathol.2010.205 PubMedCrossRef

119.

Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stohr R, Simon R, Sauter G, Leibiger H, Essers L, Weber B, Hermann K, Rosenthal A, Hartmann A, Dahl E (2004) Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 25(3):641–649PubMed

120.

Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ (2012) ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS ONE 7(3):e31127. doi:10.1371/journal.pone.0031127 PubMedPubMedCentralCrossRef

121.

Tang L, Yang J, Ng SK, Rodriguez N, Choi PW, Vitonis A, Wang K, McLachlan GJ, Caiazzo RJ Jr, Liu BC, Welch WR, Cramer DW, Berkowitz RS, Ng SW (2010) Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer 46(1):170–179. doi:10.1016/j.ejca.2009.10.003 PubMedPubMedCentralCrossRef

122.

Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13(1):11–26. doi:10.1038/nrc3419 PubMedCrossRef

123.

Zheng S, Liu J, Wu Y, Huang TL, Wang G (2015) Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics. Future Med Chem 7(18):2485–2505. doi:10.4155/fmc.15.159 PubMedCrossRef

Title: Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer
Authors: Maria Cristina Rangel
Daniel Bertolette
Nadia P. Castro
Malgorzata Klauzinska
Frank Cuttitta
David S. Salomon
Publication date: 01-04-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3746-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period

Erratum to: RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial–mesenchymal transition

Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype

Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy

The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer